# Patent

## Title
Peptide tags for the expression and purification of bioactive peptides

## Abstract

Peptide tags, referred to here as inclusion body tags, are disclosed and are useful for the generation of insoluble fusion peptides. The fusion peptides comprise at least one inclusion body tag operably linked to a peptide of interest. Expression of the fusion peptide in a host cell results in a product that is insoluble and contained within inclusion bodies in the cell and/or cell lysate. The inclusion bodies may then be purified and the protein of interest may be isolated after cleavage from the inclusion body tag.

## Background
This application claims the benefit of U.S. Provisional Application No. 60/721,329 filed Sep. 28, 2005.


FIELD OF THE INVENTION
The invention relates to the field of protein expression and purification from microbial cells. More specifically, a family of peptide tags has been discovered that are useful in the generation of insoluble fusion proteins.
BACKGROUND OF THE INVENTION
The efficient production of bioactive proteins and peptides has become a hallmark of the biomedical and industrial biochemical industry. Bioactive peptides and proteins are used as curative agents in a variety of diseases such as diabetes (insulin), viral infections and leukemia (interferon), diseases of the immune system (interleukins), and red blood cell deficiencies (erythropoietin) to name a few. Additionally, large quantities of proteins and peptides are needed for various industrial applications including, for example, the pulp and paper and pulp industries, textiles, food industries, sugar refining, wastewater treatment, production of alcoholic beverages and as catalysts for the generation of new pharmaceuticals.
With the advent of the discovery and implementation of combinatorial peptide screening technologies such as bacterial display (Kemp, D. J.; Proc. Natl. Acad. Sci. USA 78(7): 4520-4524 (1981); yeast display (Chien et al., Proc Natl Acad Sci USA 88(21): 9578-82 (1991)), combinatorial solid phase peptide synthesis (U.S. Pat. No. 5,449,754, U.S. Pat. No. 5,480,971, U.S. Pat. No. 5,585,275, U.S. Pat. No. 5,639,603), and phage display technology (U.S. Pat. No. 5,223,409, U.S. Pat. No. 5,403,484, U.S. Pat. No. 5,571,698, U.S. Pat. No. 5,837,500) new applications for peptides having specific binding affinities have been developed. In particular, peptides are being looked to as linkers in biomedical fields for the attachment of diagnostic and pharmaceutical agents to surfaces (see Grinstaff et al, U.S. Patent Application Publication No. 2003/0185870 and Linter in U.S. Pat. No. 6,620,419), as well as in the personal care industry for the attachment of benefit agents to body surfaces such as hair and skin (see commonly owned U.S. patent application Ser. No. 10/935,642, and Janssen et al. U.S. Patent Application Publication No. 2003/0152976), and in the printing industry for the attachment of pigments to print media (see commonly owned U.S. patent application Ser. No. 10/935,254).
In some cases commercially useful proteins and peptides may be synthetically generated or isolated from natural sources. However, these methods are often expensive, time consuming and characterized by limited production capacity. The preferred method of protein and peptide production is through the fermentation of recombinantly constructed organisms, engineered to over-express the protein or peptide of interest. Although preferable to synthesis or isolation, recombinant expression of peptides has a number of obstacles to be overcome in order to be a cost-effective means of production. For example, peptides (and in particular short peptides) produced in a cellular environment are susceptible to degradation from the action of native cellular proteases. Additionally, purification can be difficult, resulting in poor yields depending on the nature of the protein or peptide of interest.
One means to mitigate the above difficulties is the use the genetic chimera for protein and peptide expression. A chimeric protein or “fusion protein” is a polypeptide comprising at least one portion of the desired protein product fused to at least one portion comprising a peptide tag. The peptide tag may be used to assist protein folding, assist post expression purification, protect the protein from the action of degradative enzymes, and/or assist the protein in passing through the cell membrane.
In many cases it is useful to express a protein or peptide in insoluble form, particularly when the peptide of interest is rather short, normally soluble, and subject to proteolytic degradation within the host cell. Production of the peptide in insoluble form both facilitates simple recovery and protects the peptide from the undesirable proteolytic degradation. One means to produce the peptide in insoluble form is to recombinantly produce the peptide as part of an insoluble fusion protein by including in the fusion construct at least one peptide tag (i.e., an inclusion body tag) that induces inclusion body formation. Typically, the fusion protein is designed to include at least one cleavable peptide linker so that the peptide of interest can be subsequently recovered from the fusion protein. The fusion protein may be designed to include a plurality of inclusion body tags, cleavable peptide linkers, and regions encoding the peptide of interest.
Fusion proteins comprising a peptide tag that facilitate the expression of insoluble proteins are well known in the art. Typically, the tag portion of the chimeric or fusion protein is large, increasing the likelihood that the fusion protein will be insoluble. Example of large peptide tides typically used include, but are not limited to chloramphenicol acetyltransferase (Dykes et al., Eur. J. Biochem., 174:411 (1988), β-galactosidase (Schellenberger et al., Int. J. Peptide Protein Res., 41:326 (1993); Shen et al., Proc. Nat. Acad. Sci. USA 281:4627 (1984); and Kempe et al., Gene, 39:239 (1985)), glutathione-5-transferase (Ray et al., Bio/Technology, 11: 64 (1993) and Hancock et al. (WO94/04688)), the N-terminus of L-ribulokinase (U.S. Pat. No. 5,206,154 and Lai et al., Antimicrob. Agents & Chemo., 37:1614 (1993), bacteriophage T4 gp55 protein (Gramm et al., Bio/Technology, 12: 1017 (1994), bacterial ketosteroid isomerase protein (Kuliopulos et al., J. Am. Chem. Soc. 116:4599 (1994), ubiquitin (Pilon et al., Biotechnol. Prog., 13:374-79 (1997), bovine prochymosin (Haught et al., Biotechnol. Bioengineer. 57:55-61 (1998), and bactericidal/permeability-increasing protein (“BPI”; Better, M. D. and Gavit, P D., U.S. Pat. No. 6,242,219). The art is replete with specific examples of this technology, see for example U.S. Pat. No. 6,613,548, describing fusion protein of proteinaceous tag and a soluble protein and subsequent purification from cell lysate; U.S. Pat. No. 6,037,145, teaching a tag that protects the expressed chimeric protein from a specific protease; U.S. Pat. No. 5,648,244, teaching the synthesis of a fusion protein having a tag and a cleavable linker for facile purification of the desired protein; and U.S. Pat. No. 5,215,896; U.S. Pat. No. 5,302,526; U.S. Pat. No. 5,330,902; and US 2005221444, describing fusion tags containing amino acid compositions specifically designed to increase insolubility of the chimeric protein or peptide.
Although the above methods are useful for the expression of fusion proteins, they often incorporate large fusion tags that decrease the potential yield of desired peptide of interest. This is particularly problematic in situations where the desired protein or peptide is small. In such situations it is advantageous to use a small fusion tag to maximized yield.
There remains a need therefore for peptide fusion tags that facilitate the insolubility of fusion proteins where the peptide of interest is small and appreciably soluble in the host cell.
SUMMARY OF THE INVENTION
The stated problem has been solved though the discovery of a set of short inclusion body tags (IBTs) that are useful for synthesizing fusion proteins for increased expression and simple purification of short peptides (“peptides of interest”), especially short peptides useful in affinity applications.
The invention relates to a set of peptide inclusion body tags that may be linked to a peptide of interest to be expressed to facilitate insolubility and subsequent recovery of the expressed peptide. The inclusion body tags are generally short and may be cleaved from the fusion protein after recovery.
Accordingly the invention provides an inclusion body tag having the formula:

[Ser-(Xaa1)-(Xaa2)-[Asp]a-(Xaa3)-(Xaa4)-(Xaa5)-[Asp-Pro]b-Leu-Gln-Gln-(Xaa6)-Gln-[Asp-Pro]c]n-[R1]d 

    
    
        wherein a=0 or 1, b=0 or 1, c=0 or 1, d=0 or 1, and n=1-20 and wherein
        
            (Xaa1)=Arg or Glu;
            (Xaa2)=Arg or Glu;
            (Xaa3)=Pro or Gln;
            (Xaa4)=Arg, Glu, or Asp
            (Xaa5)=Gln or Pro;
            (Xaa6)=Arg or Glu;
        
        
        and wherein when d=1 then n=1 or 2 and R1 is selected from the group consisting of
        
            a) His-His-Gln-Gln-Gln-Gln-Glu;
            b) Ser-Leu-Gly-Tyr-Gly-Gly-Leu-Tyr-Gly-Tyr;
            c) Glu-Glu;
            d) Glu-Glu-Glu;
            e) Glu-Glu-Glu-Glu; and
            f) Glu-Glu-Glu-Glu-Glu.

wherein the inclusion body tag does not have the amino acid sequence as set forth in SEQ ID NO:139.

        
        
    
    


In an alternate embodiment the invention provides 2. An inclusion body tag comprising the structure:

[Ser-(Xaa1)-(Xaa2)-(Xaa3)-(Xaa4)-(Xaa5)-Leu-Gln-Gln-(Xaa6)-Gln]n 

wherein n=1-20,
and wherein

    
    
        (Xaa1)=Arg or Glu;
        (Xaa2)=Arg or Glu;
        (Xaa3)=Pro or Gln;
        (Xaa4)=Arg, Glu, or Asp
        (Xaa5)=Gln or Pro;
        (Xaa6)=Arg or Glu;
    
    


wherein the inclusion body tag does not have the amino acid sequence as set forth in SEQ ID NO:139.
In another embodiment, the invention provides a fusion peptide comprising at least one of the present inclusion body tags operably linked to a peptide of interest. The inclusion body tag can be a leader or trailer sequence within the fusion protein. In a preferred aspect, the fusion peptide is engineered to include at least one cleavable peptide linker that separates the inclusion body tag and the peptide of interest. In a preferred aspect, the cleavable peptide linker comprises at least one acid cleavable aspartic acid—proline (DP) moiety.
In a further embodiment, the invention provides a method for expressing a peptide of interest in insoluble form comprising:

    
    
        a) synthesizing a genetic construct encoding a fusion peptide comprising a first portion encoding the inclusion body tag of the invention operably linked to a second portion encoding a peptide of interest;
        b) transforming an expression host cell with the genetic construct of (a);
        c) growing the transformed host cell of (b) under conditions wherein the genetic construct is expressed and the encoded fusion peptide is in insoluble form; and
        d) recovering said fusion peptide in insoluble form.
    
    


In another embodiment, a method for the production of a peptide of interest is provided comprising:

    
    
        a) synthesizing a genetic construct encoding a fusion peptide comprising a first portion encoding the inclusion body tag of the invention operably linked to a second portion encoding a peptide of interest; wherein said first portion and said second portion are separated by at least one cleavable peptide linker;
        b) transforming an expression host cell with the genetic construct of (a);
        c) growing the transformed host cell of (b) under conditions wherein the genetic construct is expressed and the encoded fusion peptide is in insoluble form;
        d) recovering the fusion peptide in insoluble form;
        e) cleaving said at least one cleavable peptide linker whereby said first portion of the fusion peptide is no longer fused to the peptide of interest; and
        f) recovering said peptide of interest.
    
    


In another embodiment, the invention provides a chimeric genetic construct encoding a fusion protein comprising at least one of the present inclusion body tags and at least one peptide of interest.
In yet another embodiment, the invention provides expression vectors and microbial host cells comprising the present chimeric genetic constructs.
BRIEF DESCRIPTION OF THE BIOLOGICAL SEQUENCES
The following sequences comply with 37 C.F.R. 1.821-1.825 (“Requirements for patent applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures—the Sequence Rules”) and are consistent with World Intellectual Property Organization (WIPO) Standard ST.25 (1998) and the sequence listing requirements of the EPC and PCT
(Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administrative Instructions). The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.
A Sequence Listing is provided herewith on Compact Disk. The contents of the Compact Disk containing the Sequence Listing are hereby incorporated by reference in compliance with 37 CFR 1.52(e). The Compact Disks are submitted in triplicate and are identical to one another. The disks are labeled “Copy 1—Sequence Listing”, “Copy 2—Sequence listing”, and CRF. The disks contain the following file: CL2736 US NA.ST25 having the following size: 150,000 bytes and which was created Aug. 31, 2006.
SEQ ID NO: 1 is the nucleotide sequence of the TBP1 coding sequence encoding the TBP101 peptide.
SEQ ID NO: 2 is the amino acid sequence of the TBP101 peptide.
SEQ ID NOs: 3-7 are the nucleotide sequences of oligonucleotides used to synthesize TBP1.
SEQ ID NO: 8 and 9 are the nucleotide sequences of the primers used to PCR amplify TBP1.
SEQ ID NO: 10 is the nucleotide sequence of pENTRTM/D-TOPO® plasmid (Invitrogen, Carlsbad, Calif.).
SEQ ID NO: 11 is the nucleotide sequence of the pDEST plasmid (Invitrogen).
SEQ ID NO: 12 is the nucleotide sequence of the coding region encoding the INK101 fusion peptide.
SEQ ID NO: 13 is the amino acid sequence of the INK101 fusion peptide.
SEQ ID NO: 14 is the nucleotide sequence of plasmid pLX121.
SEQ ID NOs: 15 and 16 are the nucleotide sequences of primers used to introduce an acid cleavable aspartic acid-proline dipeptide linker into TBP101.
SEQ ID NO: 17 is the nucleotide sequence of the coding region encoding the INK101DP peptide.
SEQ ID NO: 18 is the amino acid sequence of the INK101 DP peptide (also referred to herein as “TBP101DP”).
SEQ ID NOs: 19-66 are the nucleotide sequences of oligonucleotides used to prepare the present inclusion body tags.
SEQ ID NOs: 67-90 are the amino acid sequences of the present inclusion body tags.
SEQ ID NOs: 91-136 are the nucleotide and corresponding amino acid sequences of the fusion proteins created by fusing the present inclusion body tags to the TBP101 peptide.
SEQ ID NO: 137 is the amino acid sequence of the core sequence found within many of the present inclusion body tags.
SEQ ID NO: 138 is the nucleic acid sequence of a hypothetical protein from Caenorhabditis elegans having GenBanke accession number MK68556.
SEQ ID NO: 139 is the amino acid sequence a hypothetical protein from Caenorhabditis elegans having GenBank® accession number AAK68556.
SEQ ID NOs: 140-246 are examples of amino acid sequences of body surface binding peptides, SEQ ID NOs 140-147 are skin binding peptides, SEQ ID NOs 148-240 are hair binding peptides, and SEQ ID NOs: 241-242 are nail binding peptides.
SEQ ID NOs: 243-271 are examples of antimicrobial peptide sequences.
SEQ ID NOs: 272-297 are examples of pigment binding peptides,
SEQ ID NOs: 272-275 bind carbon black, SEQ ID NOs: 276-284 are Cromophtal® yellow (Ciba Specialty Chemicals, Basel, Switzerland) binding peptides, SEQ ID NOs: 285-287 are Sunfast® magenta (Sun Chemical Corp., Parsippany, N.J.) binding peptides, and SEQ ID NOs: 288-297 are Sunfast® blue binding peptides.
SEQ ID NOs: 298-331 are examples of polymer binding peptides, SEQ ID NOs: 298-303 are cellulose binding peptides, SEQ ID NO: 304 is a poly(ethylene terephthalate) (PET) binding peptide, SEQ ID NOs: 305-316 are poly(methyl methacrylate) (PMMA) binding peptides, SEQ ID NOs: 317-322 Nylon binding peptides, and SEQ ID NOs: 323-331 are poly(tetrafluoro ethylene) (PTFE) binding peptides.
SEQ ID NO: 332 is the amino acid sequence of the Caspase-3 cleavage site that may be used as a cleavable peptide linker domain.


DETAILED DESCRIPTION OF THE INVENTION
The present invention describes a set of peptide tags (inclusion body tags) that may be coupled with a peptide of interest to form a fusion protein. The fusion protein, so assembled, is expressed in insoluble form and accumulated in inclusion bodies in the expressing host cell. The inclusion bodies may then be recovered and the desired protein cleaved from the inclusion body tag. In a preferred embodiment, the fusion protein comprises at least one cleavable peptide linker separating the inclusion body tag from the peptide of interest. In another preferred embodiment, the cleavable peptide linker comprises at least one acid cleavable aspartic acid—proline moiety.
The invention is useful for the expression and recovery of any bioactive peptides and proteins that are recombinantly expressed. Such proteins typically have high value in any number of applications including, but not limited to medical, biomedical, diagnostic, personal care, and affinity applications where the peptides of interest are used as linkers to various surfaces.
Applicants specifically incorporate the entire contents of all cited references in this disclosure. Further, when an amount, concentration, or other value or parameter is given either as a range, preferred range, or a list of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed. Where a range of numerical values is recited herein, unless otherwise stated, the range is intended to include the endpoints thereof, and all integers and fractions within the range. It is not intended that the scope of the invention be limited to the specific values recited when defining a range.
The following definitions are used herein and should be referred to for interpretation of the claims and the specification. Unless otherwise noted, all U.S. patents and U.S. patent applications referenced herein are incorporated by reference in their entirety.
As used herein, the term “comprising” means the presence of the stated features, integers, steps, or components as referred to in the claims, but that it does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
The term “invention” or “present invention” as used herein is a non-limiting term and is not intended to refer to any single embodiment of the particular invention but encompasses all possible embodiments as described in the specification and the claims.
“Open reading frame” is abbreviated ORF.
“Polymerase chain reaction” is abbreviated PCR.
As used herein, the term “isolated nucleic acid molecule” is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid molecule in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.
As used herein, the term “hair” as used herein refers to human hair, eyebrows, and eyelashes.
As used herein, the term “skin” as used herein refers to human skin, or substitutes for human skin, such as pig skin, Vitro-Skin® and EpiDermTM. Skin, as used herein, will refer to a body surface generally comprising a layer of epithelial cells and may additionally comprise a layer of endothelial cells.
As used herein, the term “nails” as used herein refers to human fingernails and toenails.
As used herein, the term “pigment” refers to an insoluble, organic or inorganic colorant.
As used herein, “HBP” means hair-binding peptide. Examples of hair binding peptides have been reported (U.S. patent application Ser. No. 11/074,473 to Huang et al.; WO 0179479; U.S. Patent Application Publication No. 2002/0098524 to Murray et al.; Janssen et al., U.S. Patent Application Publication No. 2003/0152976 to Janssen et al.; WO 04048399; U.S. Provisional Patent Application No. 60/721,329; and U.S. Provisional Patent Application No. 60/790,149).
As used herein, “SBP” means skin-binding peptide. Examples of skin binding peptides have also been reported (U.S. patent application Ser. No. 11/069,858 to Buseman-Williams; Rothe et. al., WO 2004/000257; and U.S. Provisional Patent Application No. 60/790,149).
As used herein, “NBP” means nail-binding peptide. Examples of nail binding peptides have been reported (U.S. Provisional Patent Application No. 60/790,149).
As used herein, an “antimicrobial peptide” is a peptide having the ability to kill microbial cell populations (U.S. Provisional Patent Application No. 60/790,149).
As used herein, the term “inclusion body tag” will be abbreviated “IBT” and will refer a polypeptide that facilitates formation of inclusion bodies when fused to a peptide of interest. The peptide of interest is typically soluble within the host cell and/or host cell lysate when not fused to an inclusion body tag. Fusion of the peptide of interest to the inclusion body tag produces a fusion protein that agglomerates into intracellular bodies (inclusion bodies) within the host cell. In one embodiment, the fusion protein comprises at least one portion comprising an inclusion body tag and at least one portion comprising the polypeptide of interest. In one embodiment, the protein/polypeptides of interest are separated from the inclusion body tags using cleavable peptide linker elements. As used herein, “cleavable linker elements”, “peptide linkers”, and “cleavable peptide linkers” will be used interchangeably and refer to cleavable peptide segments typically found between inclusion body tags and the peptide of interest. After the inclusion bodies are separated and/or partially-purified or purified from the cell lysate, the cleavable linker elements can be cleaved chemically and/or enzymatically to separate the inclusion body tag from the peptide of interest. The fusion peptide may also include a plurality of regions encoding one or more peptides of interest separated by one or more cleavable peptide linkers. The peptide of interest can then be isolated from the inclusion body tag, if necessary. In one embodiment, the inclusion body tag(s) and the peptide of interest exhibit different solubilities in a defined medium (typically an aqueous medium), facilitating separation of the inclusion body tag from the polypeptide of interest. In a preferred embodiment, the inclusion body tag is insoluble in an aqueous solution while the protein/polypeptide of interest is appreciably soluble in an aqueous solution. The pH, temperature, and/or ionic strength of the aqueous solution can be adjusted to facilitate recovery of the peptide of interest. In a preferred embodiment, the differential solubility between the inclusion body tag and the peptide of interest occurs in an aqueous solution having a pH of 5 to 10 and a temperature range of 15 to 50° C. The cleavable peptide linker may be from 1 to about 50 amino acids, preferably from 1 to about 20 amino acids in length. An example of an enzymatically cleavable peptide linker is provided by SEQ ID NO: 332 (Caspase-3 cleavage sequence). In a preferred embodiment, the cleavable linker is an acid cleavable aspartic acid—proline dipeptide (D-P) moiety (see INK101DP; SEQ ID NO: 18). The cleavable peptide linkers may be incorporated into the fusion proteins using any number of techniques well known in the art.
As used herein, the term “dispersant” as used herein refers to a substance that stabilizes the formation of a colloidal solution of solid pigment particles in a liquid medium. As used herein, the term “triblock dispersant” to a pigment dispersant that consists of three different units or blocks, each serving a specific function. In the present examples, a synthetic peptide encoding a peptide-based triblock dispersant was used as the “peptide of interest” to evaluate the performance of the present inclusion body tags (U.S. Ser. No. 10/935,254).
As used herein, the term “operably linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). In a further embodiment, the definition of “operably linked” may also be extended to describe the products of chimeric genes, such as fusion proteins. As such, “operably linked” will also refer to the linking of an inclusion body tag to a peptide of interest to be produced and recovered. The inclusion body tag is “operably linked” to the peptide of interest if upon expression the fusion protein is insoluble and accumulates it inclusion bodies in the expressing host cell. In a preferred embodiment, the fusion peptide will include at least on cleavable peptide linker useful in separating the inclusion body tag from the peptide of interest. In a preferred embodiment, the cleavable linker is an acid cleavable aspartic acid—proline dipeptide (D-P) moiety (see INK101DP; SEQ ID NO: 18). The cleavable peptide linkers may be incorporated into the fusion proteins using any number of techniques well known in the art.
As used herein, the terms “fusion protein”, “fusion peptide”, “chimeric protein”, and “chimeric peptide” will be used interchangeably and will refer to a polymer of amino acids (peptide, oligopeptide, polypeptide, or protein) comprising at least two portions, each portion comprising a distinct function. At least one first portion of the fusion peptide comprises at least one of the present inclusion body tags. At least one second portion of the fusion peptide comprises at least one peptide of interest. In a preferred embodiment, the fusion protein additionally includes at least one cleavable peptide linker that facilitates cleavage (chemical and/or enzymatic) and separation of the inclusion body tag(s) and the peptide(s) of interest.
Means to prepare the present peptides (inclusion body tags, cleavable peptide linkers, peptides of interest, and fusion peptides) are well known in the art and in preferred embodiments the entire peptide reagent may be prepared using the recombinant DNA and molecular cloning techniques.
As used herein, the terms “polypeptide” and “peptide” will be used interchangeably to refer to a polymer of two or more amino acids joined together by a peptide bond, wherein the peptide is of unspecified length, thus, peptides, oligopeptides, polypeptides, and proteins are included within the present definition. In one aspect, this term also includes post expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, peptides containing one or more analogues of an amino acid or labeled amino acids and peptidomimetics.
As used herein, the terms “protein of interest”, “polypeptide of interest”, “peptide of interest”, “targeted protein”, “targeted polypeptide”, “targeted peptide”, “expressible protein”, and “expressible polypeptide” will be used interchangeably and refer to a protein, polypeptide, or peptide that is bioactive and may be expressed by the genetic machinery of a host cell.
As used herein, the term “bioactive” or “peptide of interest activity” refers to the activity or characteristic associated with the peptide and/or protein of interest. The bioactive peptides may be used in a variety of applications including, but not limited to curative agents for diseases (e.g., insulin, interferon, interleukins, anti-angiogenic peptides (U.S. Pat. No. 6,815,426), and polypeptides that bind to defined cellular targets such as receptors, channels, lipids, cytosolic proteins, and membrane proteins, to name a few), peptides having antimicrobial activity, peptides having an affinity for a particular material (e.g., hair binding polypeptides, skin binding polypeptides, nail binding polypeptides, cellulose binding polypeptides, polymer binding polypeptides, clay binding polypeptides, silicon binding polypeptides, carbon nanotube binding polypeptides, and peptides that have an affinity for particular animal or plant tissues) for targeted delivery of benefit agents.
As used herein, the “benefit agent” refers to a molecule that imparts a desired functionality to the complex for a defined application. The benefit agent may be peptide of interest itself or may be one or more molecules bound to (covalently or non-covalently), or associated with, the peptide of interest wherein the binding affinity of the targeted polypeptide is used to selectively target the benefit agent to the targeted material. In another embodiment, the targeted polypeptide comprises at least one region having an affinity for at least one target material (e.g., biological molecules, polymers, hair, skin, nail, other peptides, etc.) and at least one region having an affinity for the benefit agent (e.g., pharmaceutical agents, pigments, conditioners, dyes, fragrances, etc.). In another embodiment, the peptide of interest comprises a plurality of regions having an affinity for the target material and a plurality of regions having an affinity for the benefit agent. In yet another embodiment, the peptide of interest comprises at least one region having an affinity for a targeted material and a plurality of regions having an affinity for a variety of benefit agents wherein the benefit agents may be the same of different. Examples of benefits agents may include, but are not limited to conditioners for personal care products, pigments, dye, fragrances, pharmaceutical agents (e.g., targeted delivery of cancer treatment agents), diagnostic/labeling agents, ultraviolet light blocking agents (i.e., active agents in sunscreen protectants), and antimicrobial agents (e.g., antimicrobial peptides), to name a few.
As used herein, an “inclusion body” is an intracellular amorphous deposit comprising aggregated protein found in the cytoplasm of a cell. Peptides of interest that are typically soluble with the host cell and/or cell lysates can be fused to one or more of the present inclusion body tags to facilitate formation of an insoluble fusion protein. In an alternative embodiment, the peptide of interest may be partially insoluble in the host cell, but produced at relatively lows levels where significant inclusion body formation does not occur. As such, the formation of inclusion bodies will increase protein. In a further embodiment, fusion of the peptide of interest to one or more inclusion body tags (IBTs) increases the amount of protein produced in the host cell. Formation of the inclusion body facilitates simple and efficient purification of the fusion peptide from the cell lysate using techniques well known in the art such as centrifugation and filtration. The fusion protein typically includes one or more cleavable peptide linkers used to separate the protein/polypeptide of interest from the inclusion body tag(s). The cleavable peptide linker is designed so that the inclusion body tag(s) and the protein/polypeptide(s) of interest can be easily separated by cleaving the linker element. The peptide linker can be cleaved chemically (e.g., acid hydrolysis) or enzymatically (i.e., use of a protease/peptidase that preferentially recognizes an amino acid cleavage site and/or sequence within the cleavable peptide linker).
“Codon degeneracy” refers to the nature in the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment that encodes the present amino acid sequences. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.
As used herein, the term “solubility” refers to the amount of a substance that can be dissolved in a unit volume of a liquid under specified conditions. In the present application, the term “solubility” is used to describe the ability of a peptide (inclusion body tag, peptide of interest, or fusion peptides) to be resuspended in a volume of solvent, such as a biological buffer. In one embodiment, the peptides targeted for production (“peptides of interest”) are normally soluble in the cell and/or cell lysate under normal physiological conditions. Fusion of one or more inclusion body tags (IBTs) to the target peptide results in the formation of a fusion peptide that is insoluble under normal physiological conditions, resulting in the formation of inclusion bodies. In one embodiment, the peptide of interest is insoluble in an aqueous matrix having a pH range of 5-12, preferably 6-10; and a temperature range of 5° C. to 50° C., preferably 10° C. to 40° C. Fusion of the peptide of interest to at least one of the present inclusion body tags results in the formation of an insoluble fusion protein that agglomerates into at least one inclusion body under normal physiological conditions.
The term “amino acid” refers to the basic chemical structural unit of a protein or polypeptide. The following abbreviations are used herein to identify specific amino acids:













Three-Letter
One-Letter


Amino Acid
Abbreviation
Abbreviation







Alanine
Ala
A


Arginine
Arg
R


Asparagine
Asn
N


Aspartic acid
Asp
D


Cysteine
Cys
C


Glutamine
Gln
Q


Glutamic acid
Glu
E


Glycine
Gly
G


Histidine
His
H


Isoleucine
Ile
I


Leucine
Leu
L


Lysine
Lys
K


Methionine
Met
M


Phenylalanine
Phe
F


Proline
Pro
P


Serine
Ser
S


Threonine
Thr
T


Tryptophan
Trp
W


Tyrosine
Tyr
Y


Valine
Val
V


Miscellaneous (or as defined by the
Xaa
X


present formulas)









“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5′ non-coding sequences) and following (3′ non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences “Chimeric gene” refers to any gene that is not a native gene, comprising regulatory and coding sequences (including coding regions engineered to encode fusion peptides) that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. A “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes.
As used herein, the term “coding sequence” refers to a DNA sequence that encodes for a specific amino acid sequence. “Suitable regulatory sequences” refer to nucleotide sequences located upstream (5′ non-coding sequences), within, or downstream (3′ non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, enhancers, ribosomal binding sites, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing site, effector binding sites, and stem-loop structures. One of skill in the art recognizes that selection of suitable regulatory sequences will depend upon host cell and/or expression system used.
As used herein, the term “genetic construct” refers to a series of contiguous nucleic acids useful for modulating the genotype or phenotype of an organism. Non-limiting examples of genetic constructs include but are not limited to a nucleic acid molecule, and open reading frame, a gene, a plasmid and the like.
As used herein, the term “expression ranking” means the relative yield of insoluble fusion protein estimated visually and scored on a relative scale of 0 (no insoluble fusion peptide) to 3 (highest yield of insoluble fusion peptide). As described in the present examples, the relative yield of insoluble fusion protein was estimated visually from stained polyacrylamide gels.
As used herein, the term “transformation” refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. As used herein, the host cell's genome is comprised of chromosomal and extrachromosomal (e.g., plasmid) genes. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” or “recombinant” or “transformed” organisms. As used herein, the term “host cell” refers to cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.
As used herein, the terms “plasmid”, “vector” and “cassette” refer to an extrachromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3′ untranslated sequence into a cell. “Transformation cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitates transformation of a particular host cell. “Expression cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.
Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001) (hereinafter “Maniatis”); and by Silhavy, T. J., Bennan, M. L. and Enquist, L. W., Experiments with Gene Fusions, Cold Spring Harbor Laboratory Cold Press Spring Harbor, N.Y. (1984); and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience (1987).
Inclusion Body Tags
Amyloid-type proteins, typically rich in the amino acids glutamine, asparagine, and proline are naturally-occurring proteins known to readily precipitate under physiological conditions. A search of the publicly available databases for glutamine rich proteins was conducted and a hypothetical protein from Caenorhabditis elegans was identified (GenBank® accession number MK68556; Basham, V. M., Science, 282 (5389), 2012-2018 (1998); SEQ ID NOs: 138 and 139). This protein was selected as the starting material for preparation of the present inclusion body tags. Short regions ( ̃10 amino acids) of the C. elegans protein were evaluated for their ability to act as a suitable inclusion body tag. From this protein, inclusion body tag #24 (IBT-24; SEQ ID NO: 70) was prepared.
A series of IBT-24 analogues were prepared and evaluated. Several approaches were taken including varying copy number (e.g., IBT-3), altering the charge of the tag (e.g., IBT-26 or IBT-35), and adding different amino acid units (e.g., IBT-95). The present inclusion body tags are provided in Table 3.
One set of analogues examined the effects of exchanging the positively charged arginine (R) residues (of which there are eight in IBT-3) for negatively charged glutamic acid (E) residues. Increasing the number or R→E substitutions decreased the isoelectric point of the tag. A second set of IBT-3 analogues added varying lengths of negatively charged glutamic acid to the C-terminus of IBT-3. This modification added a significant amount of localized negative charge to the fusion tag, neutralizing the positive charge supplied by the arginine residues. Each of the present fusion tags was fused to a standard peptide of interest derived from TBP101 (SEQ ID NO: 2). The peptide of interest (when not linked to an inclusion body tag) is soluble under physiological conditions. Each fusion peptide was recombinantly expressed in an appropriate host cell and evaluated for insoluble fusion peptide formation.
Several inclusion body tags were identified that were effective in creating insoluble fusion peptides. The amino acid sequence of the present inclusion body tags can be defined by Formula 1:

[Ser-(Xaa1)-(Xaa2)-[Asp]a-(Xaa3)-(Xaa4)-(Xaa5)-[Asp-Pro]b-Leu-Gln-Gln-(Xaa6)-Gln-[Asp-Pro]c]n-[R1]d  Formula 1.

wherein a=0 or 1, b=0 or 1, c=0 or 1, d=0 or 1, and n=1-20
and wherein
(Xaa1)=Arg or Glu;
(Xaa2)=Arg or Glu;
(Xaa3)=Pro or Gln;
(Xaa4)=Arg, Glu, or Asp
(Xaa5)=Gln or Pro;
(Xaa6)=Arg or Glu;


    
    
        and wherein when d=1 then n=1 or 2 and R1 is selected from the group consisting of
        
            a) His-His-Gln-Gln-Gln-Gln-Glu;
            b) Ser-Leu-Gly-Tyr-Gly-Gly-Leu-Tyr-Gly-Tyr;
            c) Glu-Glu;
            d) Glu-Glu-Glu;
            e) Glu-Glu-Glu-Glu; and
            f) Glu-Glu-Glu-Glu-Glu.
        
        
    
    


In one embodiment, n=1 to 20, preferably 1 to 10, more preferably 1 to 5, and most preferably 1 to 2.
In another embodiment, the present inclusion body tags comprise Formula 1 with the proviso that the inclusion body tag is not equal to SEQ ID NO: 139.
The present fusion tags were developed from IBT-24 (SEQ ID NO: 70). As such, and in another embodiment, the present inclusion body tags typically comprise a core amino sequence defined by Formula 2 (SEQ ID NO: 137):

[Ser-(Xaa1)-(Xaa2)-(Xaa3)-(Xaa4)-(Xaa5)-Leu-Gln-Gln-(Xaa6)-Gln]n  Formula 2.

wherein the amino acids for Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6, and value range of “n” are as defined above. In yet another embodiment, the present inclusion body tags comprise Formula 2 wherein the inclusion body tag does not include the entire amino acid sequence of the C. elegans hypothetical protein (SEQ ID NO: 139).

In another embodiment, the core amino acid sequence may include at least one Asp residue and/or an Asp-Pro residue pair inserted internally or added to the amino or carboxyl terminal of the core amino acid sequence (SEQ ID NO: 137).
The present inclusion body tags are less than 200 amino acids in length, preferably less than 125 amino acid residues in length, more preferably less than 75 amino acid residues, even more preferably less than 50 amino acid residues, and yet even more preferably less than 30 amino acid residues in length, and most preferably about 15 amino acid residues in length.
In one embodiment, the present inclusion body tags are selected from the group consisting of SEQ ID NOs: 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 81, 82, 83, 84, 87, 88, 89, 90, and 137. Preferred for use herein are inclusion body tags comprising the core sequence as defined by SEQ ID NO: 137, with the proviso that the inclusion body tag sequence is not identical to SEQ ID NO: 139.
Examples of inclusion bodies defined by Formula 1 were evaluated in terms of expression ranking as shown in Table 4. An amino acid sequence alignment of the present inclusion body tag sequences is provided in Table 5.
Expressible Peptides of Interest
The peptide of interest (“expressible peptide”) targeted for production using the present method is one that is appreciably soluble in the host cell and/or host cell liquid lysate under normal physiological conditions. In a preferred aspect, the peptides of interest are generally short (<50 amino acids in length) and difficult to produce in sufficient amounts due to proteolytic degradation. Fusion of the peptide of interest to at least one of the present inclusion body forming tags creates a fusion peptide that is insoluble in the host cell and/or host cell lysate under normal physiological conditions. Production of the peptide of interest is typically increased when expressed and accumulated in the form of an insoluble inclusion body as the peptide is generally more protected from proteolytic degradation. Furthermore, the insoluble fusion protein can be easily separated from the host cell lysate using centrifugation or filtration.
In general, the present inclusion body tags can be used in a process to produce any peptide of interest that is (1) typically soluble in the cell and/or cell lysate under typical physiological conditions and/or (2) those that can be produced at significantly higher levels when expressed in the form of an inclusion body. In a preferred embodiment, the peptide of interest is appreciably soluble in the host cell and/or corresponding cell lysate under normal physiological and/or process conditions.
The length of the peptide of interest may vary as long as (1) the peptide is appreciably soluble in the host cell and/or cell lysate, and/or (2) the amount of the targeted peptide produced is significantly increased when expressed in the form of an insoluble fusion peptide/inclusion body (i.e. expression in the form of a fusion protein protect the peptide of interest from proteolytic degradation). Typically the peptide of interest is less than 200 amino acids in length, preferably less than 100 amino acids in length, more preferably less than 75 amino acids in length, even more preferably less than 50 amino acids in length, and most preferably less than 25 amino acids in length.
The function of the peptide of interest is not limited by the present method and may include, but is not limited to bioactive molecules such as curative agents for diseases (e.g., insulin, interferon, interleukins, peptide hormones, anti-angiogenic peptides, and peptides that bind to and affect defined cellular targets such as receptors, channels, lipids, cytosolic proteins, and membrane proteins; see U.S. Pat. No. 6,696,089,), peptides having an affinity for a particular material (e.g., biological tissues, biological molecules, hair binding peptides (U.S. patent application Ser. No. 11/074,473; WO 0179479; U.S. Patent Application Publication No. 2002/0098524; U.S. Patent Application Publication No. 2003/0152976; WO 04048399; U.S. Provisional Patent Application No. 60/721,329; and U.S. Provisional Patent Application No. 60/790,149)., skin binding peptides (U.S. patent application Ser. No. 11/069,858; WO 2004/000257; and U.S. Provisional Patent Application No. 60/790,149), nail binding peptides (U.S. Provisional Patent Application No. 60/790,149), cellulose binding peptides, polymer binding peptides (U.S. Provision Patent Application Nos. 60/750,598, 60/750,599, 60/750,726, 60/750,748, and 60/750,850), clay binding peptides, silicon binding peptides, and carbon nanotube binding peptides) for targeted delivery of at least one benefit agent (see U.S. patent application Ser. No. 10/935,642; U.S. patent application Ser. No. 11/074,473; and U.S. Provisional Patent Application No. 60/790,149).
In a preferred aspect, the peptide of interest is selected from the group of hair binding peptides, skin binding peptides, nail binding peptides, antimicrobial peptides, pigment binding peptides and polymer binding peptides. In another preferred aspect, the peptide of interest is selected from the group consisting of a hair binding peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 148 to 240, a skin binding peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 140 to 147, a nail binding peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 241 and 242 and a pigment binding peptide selected from the group consisting of SEQ ID NO: 272-297.
As used herein, the “benefit agent” refers to a molecule that imparts a desired functionality to a target material (e.g., hair, skin, etc.) for a defined application (U.S. patent application Ser. No. 10/935,642; U.S. patent application Ser. No. 11/074,473; and U.S. Patent Application 60/790,149 for a list of typical benefit agents such as conditioners, pigments/colorants, fragrances, etc.). The benefit agent may be peptide of interest itself or may be one or more molecules bound to (covalently or non-covalently), or associated with, the peptide of interest wherein the binding affinity of the peptide of interest is used to selectively target the benefit agent to the targeted material. In another embodiment, the peptide of interest comprises at least one region having an affinity for at least one target material (e.g., biological molecules, polymers, hair, skin, nail, other peptides, etc.) and at least one region having an affinity for the benefit agent (e.g., pharmaceutical agents, antimicrobial agents, pigments, conditioners, dyes, fragrances, etc.). In another embodiment, the peptide of interest comprises a plurality of regions having an affinity for the target material and a plurality of regions having an affinity for one or more benefit agents. In yet another embodiment, the peptide of interest comprises at least one region having an affinity for a targeted material and a plurality of regions having an affinity for a variety of benefit agents wherein the benefit agents may be the same of different. Examples of benefits agents may include, but are not limited to conditioners for personal care products, pigments, dye, fragrances, pharmaceutical agents (e.g., targeted delivery of cancer treatment agents), diagnostic/labeling agents, ultraviolet light blocking agents (i.e., active agents in sunscreen protectants), and antimicrobial agents (e.g., antimicrobial peptides), to name a few.
Cleavable Peptide Linkers
The use of cleavable peptide linkers is well known in the art. Fusion peptides comprising the present inclusion body tags will typically include at least one cleavable sequence separating the inclusion body tag from the polypeptide of interest. The cleavable sequence facilitates separation of the inclusion body tag(s) from the peptide(s) of interest. In one embodiment, the cleavable sequence may be provided by a portion of the inclusion body tag and/or the peptide of interest (e.g., inclusion of a acid cleavable aspartic acid—proline moiety). In a preferred embodiment, the cleavable sequence is provided by including (in the fusion peptide) at least one cleavable peptide linker between the inclusion body tag and the peptide of interest.
Means to cleave the peptide linkers are well known in the art and may include chemical hydrolysis, enzymatic cleavage agents, and combinations thereof. In one embodiment, one or more chemically cleavable peptide linkers are included in the fusion construct to facilitate recovery of the peptide of interest from the inclusion body fusion protein. Examples of chemical cleavage reagents include cyanogen bromide (cleaves methionine residues), N-chloro succinimide, iodobenzoic acid or BNPS-skatole [2-(2-nitrophenylsulfenyl)-3-methylindole] (cleaves tryptophan residues), dilute acids (cleaves at aspartyl-prolyl bonds), and hydroxylamine (cleaves at asparagine-glycine bonds at pH 9.0); see Gavit, P. and Better, M., J. Biotechnol., 79:127-136 (2000); Szoka et al., DNA, 5(1):11-20 (1986); and Walker, J. M., The Proteomics Protocols Handbook, 2005, Humana Press, Totowa, N.J.)). In a preferred embodiment, one or more aspartic acid—proline acid cleavable recognition sites (i.e., a cleavable peptide linker comprising one or more D-P dipeptide moieties) are included in the fusion protein construct to facilitate separation of the inclusion body tag(s) form the peptide of interest. In another embodiment, the fusion peptide may include multiple regions encoding peptides of interest separated by one or more cleavable peptide linkers.
In another embodiment, one or more enzymatic cleavage sequences are included in the fusion protein construct to facilitate recovery of the peptide of interest. Proteolytic enzymes and their respective cleavage site specificities are well known in the art. In a preferred embodiment, the proteolytic enzyme is selected to specifically cleave only the peptide linker separating the inclusion body tag and the peptide of interest. Examples of enzymes useful for cleaving the peptide linker include, but are not limited to Arg-C proteinase, Asp-N endopeptidase, chymotrypsin, clostripain, enterokinase, Factor Xa, glutamyl endopeptidase, Granzyme B, Achromobacter proteinase I, pepsin, proline endopeptidase, proteinase K, Staphylococcal peptidase I, thermolysin, thrombin, trypsin, and members of the Caspase family of proteolytic enzymes (e.g. Caspases 1-10) (Walker, J. M., supra). An example of a cleavage site sequence is provided by SEQ ID NO: 332 (Caspase-3 cleavage site; Thornberry et al. J. Biol. Chem., 272:17907-17911 (1997) and Tyas et al., EMBO Reports, 1 (3):266-270 (2000)). Typically, the cleavage step occurs after the insoluble inclusion bodies and/or insoluble fusion peptides are isolated from the cell lysate. The cells can be lysed using any number of means well known in the art (e.g. mechanical and/or chemical lysis). Methods to isolate the insoluble inclusion bodies/fusion peptides from the cell lysate are well known in the art (e.g., centrifugation, filtration, and combinations thereof). Once recovered from the cell lysate, the insoluble inclusion bodies and/or fusion peptides can be treated with a cleavage agent (chemical or enzymatic) to cleavage the inclusion body tag from the peptide of interest. In one embodiment, the fusion protein and/or inclusion body is diluted and/or dissolved in a suitable solvent prior to treatment with the cleavage agent. In a further embodiment, the cleavage step may be omitted if the inclusion body tag does not interfere with the activity of the peptide of interest. After the cleavage step, and in a preferred embodiment, the peptide of interest can be separated and/or isolated from the fusion protein and the inclusion body tags based on a differential solubility of the components. Parameters such as pH, salt concentration, and temperature may be adjusted to facilitate separation of the inclusion body tag from the peptide of interest. In one embodiment, the peptide of interest is soluble while the inclusion body tag and/or fusion protein is insoluble in the defined process matrix (typically an aqueous matrix). In another embodiment, the peptide of interest is insoluble while the inclusion body tag is soluble in the defined process matrix.
In another embodiment, the peptide of interest may be further purified using any number of well known purification techniques in the art such as ion exchange, gel purification techniques, and column chromatography (see U.S. Pat. No. 5,648,244), to name a few.
Fusion Peptides
The present inclusion body tags are used to create chimeric polypeptides (“fusion peptides” or “fusion proteins”) that are insoluble within the host cell, forming inclusion bodies. Synthesis and expression of expressible genetic constructs encoding the present fusion peptides is well known to one of skill in the art given the present inclusion body tags.
The present fusion peptides will include at least one of the present inclusion body tags (IBTs) operably linked to at least one peptide of interest. Typically, the fusion peptides will also include at least one cleavable peptide linker having a cleavage site between the inclusion body tag and the peptide of interest. In one embodiment, the inclusion body tag may include a cleavage site whereby inclusion of a separate cleavable peptide linker may not be necessary. In a preferred embodiment, the cleavage method is chosen to ensure that the peptide of interest is not adversely affected by the cleavage agent(s) employed. In a further embodiment, the peptide of interest may be modified to eliminate possible cleavage sites with the peptide so long as the desired activity of the peptide is not adversely affected.
One of skill in the art will recognize that the elements of the fusion protein can be structured in a variety of ways. Typically, the fusion protein will include at least one IBT, at least one peptide of interest (POI), and at least one cleavable linker (CL) located between the IBT and the POI. The inclusion body tag may be organized as a leader sequence or a terminator sequence relative to the position of the peptide of interest within the fusion peptide. In another embodiment, a plurality of IBTs, POIs, and CLs are used when engineering the fusion peptide. In a further embodiment, the fusion peptide may include a plurality of IBTs (as defined herein), POIs, and CLs that are the same or different.
The fusion peptide should be insoluble in an aqueous matrix at a temperature of 10° C. to 50° C., preferably 10° C. to 40° C. The aqueous matrix typically comprises a pH range of 5 to 12, preferably 6 to 10, and most preferably 6 to 8. The temperature, pH, and/or ionic strength of the aqueous matrix can be adjusted to obtain the desired solubility characteristics of the fusion peptide/inclusion body.
Method to Make a Peptide of Interest Using Insoluble Fusion Peptides
The present inclusion body tags are used to make fusion peptides that form inclusion bodies within the production host. This method is particularly attractive for producing significant amounts of soluble peptide of interest that (1) are difficult to isolation from other soluble components of the cell lysate and/or (2) are difficult to product in significant amounts within the target production host.
In the present methods, a peptide of interest is fused to at least one of the present inclusion body tags, forming an insoluble fusion protein. Expression of the genetic construct encoding the fusion protein produces an insoluble form of the peptide of interest that accumulates in the form of inclusion bodies within the host cell. The host cell is grown for a period of time sufficient for the insoluble fusion peptide to accumulate within the cell.
The host cell is subsequently lysed using any number of techniques well known in the art. The insoluble fusion peptide/inclusion bodies are then separated from the soluble components of the cell lysate using a simple and economical technique such as centrifugation and/or membrane filtration. The insoluble fusion peptide/inclusion body can then be further processed in order to isolate the peptide of interest. Typically, this will include re-suspension of the fusion peptide/inclusion body in a liquid matrix suitable for cleaving the fusion peptide, separating the inclusion body tag from the peptide of interest. The fusion protein is typically designed to include a cleavable peptide linker separating the inclusion body tag from the peptide of interest. The cleavage step can be conducted using any number of techniques well known in the art (chemical cleavage, enzymatic cleavage, and combinations thereof). The peptide of interest can then be separated from the inclusion body tag(s) and/or fusion peptides using any number of techniques well known in the art (centrifugation, filtration, precipitation, column chromatography, etc.). Preferably, the peptide of interest (once cleaved from fusion peptide) has a solubility that is significantly different than that of the inclusion body tag and/or remaining fusion peptide.
Transformation and Expression
Once the inclusion body tag has been identified and paired with the appropriate peptide of interest, construction of cassettes and vectors that may be transformed in to an appropriate expression host is common and well known in the art. Typically, the vector or cassette contains sequences directing transcription and translation of the relevant chimeric gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5′ of the gene which harbors transcriptional initiation controls and a region 3′ of the DNA fragment which controls transcriptional termination. It is most preferred when both control regions are derived from genes homologous to the transformed host cell, although it is to be understood that such control regions need not be derived from the genes native to the specific species chosen as a production host.
Transcription initiation control regions or promoters, which are useful to drive expression of the genetic constructs encoding the fusion peptides in the desired host cell, are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these constructs is suitable for the present invention including but not limited to CYC1, HIS3, GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI (useful for expression in Saccharomyces); AOX1 (useful for expression in Pichia); and lac, ara (pBAD), tet, trp, IPL, IPR, T7, tac, and trc (useful for expression in Escherichia coli) as well as the amy, apr, npr promoters and various phage promoters useful for expression in Bacillus. 
Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary, however, it is most preferred if included.
Preferred host cells for expression of the present fusion peptides are microbial hosts that can be found broadly within the fungal or bacterial families and which grow over a wide range of temperature, pH values, and solvent tolerances. For example, it is contemplated that any of bacteria, yeast, and filamentous fungi will be suitable hosts for expression of the present nucleic acid molecules encoding the fusion peptides. Because of transcription, translation, and the protein biosynthetic apparatus is the same irrespective of the cellular feedstock, genes are expressed irrespective of the carbon feedstock used to generate the cellular biomass. Large-scale microbial growth and functional gene expression may utilize a wide range of simple or complex carbohydrates, organic acids and alcohols (i.e. methanol), saturated hydrocarbons such as methane or carbon dioxide in the case of photosynthetic or chemoautotrophic hosts. However, the functional genes may be regulated, repressed or depressed by specific growth conditions, which may include the form and amount of nitrogen, phosphorous, sulfur, oxygen, carbon or any trace micronutrient including small inorganic ions. In addition, the regulation of functional genes may be achieved by the presence or absence of specific regulatory molecules that are added to the culture and are not typically considered nutrient or energy sources. Growth rate may also be an important regulatory factor in gene expression. Examples of host strains include, but are not limited to fungal or yeast species such as Aspergillus, Trichoderma, Saccharomyces, Pichia; Candida, Hansenula, or bacterial species such as Salmonella, Bacillus, Acinetobacter, Zymomonas, Agrobacterium, Erythrobacter, Chlorobium, Chromatium, Flavobacterium, Cytophaga, Rhodobacter, Rhodococcus, Streptomyces, Brevibacterium, Corynebacteria, Mycobacterium, Deinococcus, Escherichia, Erwinia, Pantoea, Pseudomonas, Sphingomonas, Methylomonas, Methylobacter, Methylococcus, Methylosinus, Methylomicrobium, Methylocystis, Alcaligenes, Synechocystis, Synechococcus, Anabaena, Thiobacillus, Methanobacterium, Klebsiella, and Myxococcus. Preferred bacterial host strains include Escherichia and Bacillus. In a highly preferred aspect, the host strain is Escherichia coli. 

Fermentation Media

Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates may include but are not limited to monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose or mixtures thereof and unpurified mixtures from renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally the carbon substrate may also be one-carbon substrates such as carbon dioxide, or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated. In addition to one and two carbon substrates methylotrophic organisms are also known to utilize a number of other carbon containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al., Microb. Growth C1 Compd., [Int. Symp.], 7th (1993), 415-32. Editor(s): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of Candida will metabolize alanine or oleic acid (Sulter et al., Arch. Microbiol. 153:485-489 (1990)). Hence it is contemplated that the source of carbon utilized in the present invention may encompass a wide variety of carbon containing substrates and will only be limited by the choice of organism.
Although it is contemplated that all of the above mentioned carbon substrates and mixtures thereof are suitable in the present invention, preferred carbon substrates are glucose, fructose, and sucrose.
In addition to an appropriate carbon source, fermentation media must contain suitable minerals, salts, cofactors, buffers and other components, known to those skilled in the art, suitable for the growth of the cultures and promotion of the expression of the present fusion peptides.
Culture Conditions
Suitable culture conditions can be selected dependent upon the chosen production host. Typically, cells are grown at a temperature in the range of about 25° C. to about 40° C. in an appropriate medium. Suitable growth media in the present invention are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth or Yeast medium (YM) broth. Other defined or synthetic growth media may also be used and the appropriate medium for growth of the particular microorganism will be known by one skilled in the art of microbiology or fermentation science. The use of agents known to modulate catabolite repression directly or indirectly, e.g., cyclic adenosine 2′:3′-monophosphate, may also be incorporated into the fermentation medium.
Suitable pH ranges for the fermentation are typically between pH 5.0 to pH 9.0, where pH 6.0 to pH 8.0 is preferred.
Fermentations may be performed under aerobic or anaerobic conditions where aerobic conditions are generally preferred.
Industrial Batch and Continuous Fermentations
A classical batch fermentation is a closed system where the composition of the medium is set at the beginning of the fermentation and not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the medium is inoculated with the desired organism or organisms, and fermentation is permitted to occur without adding anything to the system. Typically, a “batch” fermentation is batch with respect to the addition of carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. In batch systems the metabolite and biomass compositions of the system change constantly up to the time the fermentation is stopped. Within batch cultures cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase will eventually die. Cells in log phase generally are responsible for the bulk of production of end product or intermediate.
A variation on the standard batch system is the Fed-Batch system. Fed-Batch fermentation processes are also suitable in the present invention and comprise a typical batch system with the exception that the substrate is added in increments as the fermentation progresses. Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the media. Measurement of the actual substrate concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO2. Batch and Fed-Batch fermentations are common and well known in the art and examples may be found in Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, Mass. (hereinafter “Brock”), or Deshpande, Mukund V., Appl. Biochem. Biotechnol., 36:227, (1992).
Although the present invention is performed in batch mode it is contemplated that the method would be adaptable to continuous fermentation methods. Continuous fermentation is an open system where a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned media is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.
Continuous fermentation allows for the modulation of one factor or any number of factors that affect cell growth or end product concentration. For example, one method will maintain a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate. In other systems a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions and thus the cell loss due to the medium being drawn off must be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, supra.
It is contemplated that the present invention may be practiced using either batch, fed-batch or continuous processes and that any known mode of fermentation would be suitable.
EXAMPLES
The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various uses and conditions.

The meaning of abbreviations used is as follows: “min” means minute(s), “h” means hour(s), “μL” means microliter(s), “mL” means milliliter(s), “L” means liter(s), “nm” means nanometer(s), “mm” means millimeter(s), “cm” means centimeter(s), “μm” means micrometer(s), “mM” means millimolar, “M” means molar, “mmol” means millimole(s), “μmol” means micromole(s), “pmol” means picomole(s), “g” means gram(s), “μg” means microgram(s), “mg” means milligram(s), “g” means the gravitation constant, “rpm” means revolutions per minute, “DTT” means dithiothreitol, and “cat#” means catalog number.

General Methods
Standard recombinant DNA and molecular cloning techniques used in the Examples are well known in the art and are described by Maniatis, (supra); Silhavy et al., (supra); and Ausubel et al., (supra).
Materials and methods suitable for the maintenance and growth of bacterial cultures are also well known in the art. Techniques suitable for use in the following Examples may be found in Manual of Methods for General Bacteriology, Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds., American Society for Microbiology, Washington, D.C., 1994, or in Brock (supra). All reagents, restriction enzymes and materials used for the growth and maintenance of bacterial cells were obtained from BD Diagnostic Systems (Sparks, Md.), Invitrogen (Carlsbad, Calif.), Life Technologies (Rockville, Md.), QIAGEN (Valencia, Calif.) or Sigma-Aldrich Chemical Company (St. Louis, Mo.), unless otherwise specified.
Example 1
Preparation of Plasmid pLX121 for Evaluating Inclusion Body Tag Performance
A genetic construct was prepared for evaluating the performance of the present inclusion body tags when fused to a soluble peptide of interest. The peptide of interest used in the present examples was prepared from a previously reported peptide-based triblock dispersant (U.S. Ser. No. 10/935,254).
Cloning of the TBP1 Gene
The TBP1 gene, encoding the TBP1 peptide, was selected for evaluation of the present inclusion body tags. The synthetic TBP1 peptide is peptide-based triblock dispersant comprising a carbon-black binding domain, a hydrophilic peptide linker, and a cellulose binding domain (see Example 15 of U.S. patent application Ser. No. 10/935,254, herein incorporated by reference).
The TBP1 gene (SEQ ID NO: 1) encoding the 68 amino acid peptide TBP101 (SEQ ID NO: 2) was assembled from synthetic oligonucleotides (Sigma-Genosys, Woodlands, Tex.; Table 1).







TABLE 1







Oligonucleotides Used to Prepare the TBP1









Oligonucleotide
Nucleotide Sequence
SEQ ID


Name
(5′-3′)
NO:





TBP1 (+)1
GGATCCATCGAAGGTCGTTTCCACGA
3



AAACTGGCCGTCTGGTGGCGGTACCTC



TACTTCCAAAGCTTCCACCACTACGAC



TTCTAGCAAAACCACCACTACAT


 


TBP1 (+)2
CCTCTAAGACTACCACGACTACCTCCA
4



AAACCTCTACTACCTCTAGCTCCTCTA



CGGGCGGTGGCACTCACAAGACCTCT



ACTCAGCGTCTGCTGGCTGCATAA


 


TBP1 (−)1
TTATGCAGCCAGCAGACGCTGAGTAG
5



AGGTCTTGTGAGTGCCACCGCCCGTA



GAGGAGCTAGAGGTAGT


 


TBP1 (−)2
AGAGGTTTTGGAGGTAGTCGTGGTAG
6



TCTTAGAGGATGTAGTGGTGGTTTTG



CTAGAAGTCGTAGTGGT


 


TBP1 (−)3
GGAAGCTTTGGAAGTAGAGGTACCGC
7



CACCAGACGGCCAGTTTTCGTGGAAA



CGACCTTCGATGGATCC









Each oligonucleotide was phosphorylated with ATP using T4 polynucleotide kinase. The resulting oligonucleotides were mixed, boiled for 5 min, and then cooled to room temperature slowly. Finally, the annealed oligonucleotides were ligated with T4 DNA ligase to give synthetic DNA fragment TBP1, given as SEQ ID NO: 1, which encodes the TBP101 peptide.
Construction of pINK101 Expression Plasmid:
Lambda phage site-specific recombination was used for preparation and expression of the present fusion proteins (GatewayTM System; Invitrogen, Carlsbad, Calif.). TBP1 was integrated into the GatewayTM system for protein over-expression. In the first step, 2 μL of the TBP1 ligation mixture was used in a 50-μL PCR reaction. Reactions were catalyzed by Pfu DNA polymerase (Stratagene, La Jolla, Calif.), following the standard PCR protocol. Primer 5′TBP1 (5′-CACCGGATCCATCGAAGGTCGT-3′; SEQ ID NO: 8) and 3′TBP1 (5′-TCATTATGCAGCCAGCAGCGC-3′; SEQ ID NO: 9) were used for amplification of the TBP1 fragment. Due to the design of these primers, an additional sequence of CACC and another stop codon TGA were added to the 5′ and 3′ ends of the amplified fragments.
The amplified TBP1 was directly cloned into pENTRTM/D-TOPO® vector (SEQ ID NO: 10) using Invitrogen's pENTRTM directional TOPO® cloning kit (Invitrogen; Catalog K2400-20), resulting in the GatewayTM entry plasmid pENTR-TBP1. This entry plasmid was propagated in One Shots TOP10 E. coli cells (Invitrogen). The accuracy of the PCR amplification and cloning procedures were confirmed by DNA sequencing analysis. The entry plasmid was mixed with pDEST17 (Invitrogen, SEQ ID NO: 11). LR recombination reactions were catalyzed by LR ClonaseTM (Invitrogen). The destination plasmid, pINK101 was constructed and propagated in the DH5α E. coli strain. The accuracy of the recombination reaction was determined by DNA sequencing. All reagents for LR recombination reactions (i.e., lambda phage site-specific recombination) were provided in Invitrogen's E. coli expression system with the GatewayTM Technology kit. The site-specific recombination process followed the manufacturer's instructions (Invitrogen).
The resulting plasmid, named pINK101, contains the coding regions for recombinant protein 6H-TBP1, named INK101 (SEQ ID NOs 12 and 13), which is an 11.6 kDa protein. The protein sequence includes a 6×His tag and a 24 amino acid linker that includes Factor Xa protease recognition site before the sequence of the TBP101 peptide.
The amino acid coding region for the 6×His tag and the following linker comprising the Factor Xa protease recognition site were excised from pINK101 by digestion with the NdeI and BamHI restriction enzymes.
The TBP1 gene (SEQ ID NO: 1) encodes a polypeptide (SEQ ID NO: 2) having a ST linker flanked by Gly-Gly-Gly amino acids. The system was made more modular by further mutagenesis to change the upstream amino acid sequence from Gly-Gly-Gly to Ala-Gly-Gly (codon GGT changed to GCC) and the downstream Gly-Gly-Gly to Gly-Gly-Ala (codon GGT GGC changed to GGC GCC). These changes provided a NgoMl restriction site and a Kasl restriction site flanking the ST linker, thus facilitating replacement of any element in TBP1.
Further modifications were made to TBP101 including the addition of an acid cleavable site to facilitate the removal of any tag sequence encoded by the region between the NdeI and BamHI sites of the expression plasmid. The resulting plasmid was called pLX121 (also referred to as “pINKO11DP”; SEQ ID NO: 14). These modifications changed the amino acids E-G to D-P (acid cleavable aspartic acid—proline linkage) using the Stratagene QuikChange® II Site-Directed Mutagenesis Kit Cat# 200523 (La Jolla, Calif.) as per the manufacturer's protocol using the primers INK101+(5′-CCCCTTCACCGGATCCATCGATCCACGTTTCCACGAAAACTGGCC-3′; SEQ ID 15) and INK101-(5′-GGCCAGTTTTCGTGGAAACGTGGATCGATGGATCCGGTGAAGGGG-3′; SEQ ID NO 16). The sequences were confirmed by DNA sequence analysis. The coding region and the corresponding amino acid sequence of the modified protein, INK101DP, is provided as SEQ ID NOs 17 and 18, respectively. INK101 DP (also referred to herein as “TBP101 DP”) was used to evaluate the present inclusion body tags.
INK101DP Peptide (SEQ ID NO: 18)
MSYYHHHHHHLESTSLYKKAGSAAAPFTGSIDPRFHENWPSAGGTSTSKASTTTTSSKTTTTSSKTTTTTSKTSTTSSSSTGGATHKTSTQRLLAA
The aspartic acid—proline acid cleavable linker is bolded. The DP moiety replaced the EG moiety found in the unmodified TBP101 peptide. The modified TBP101 peptide (i.e., peptide of interest) is underlined.
Example 2
Construction Inclusion Body Tag 3 (IBT-3)
The test system expression vector pLX121 has two unique restriction endonuclease sites (NdeI and BamHI) facilitating inclusion body fusion partner replacement in-frame with the INK101DP peptide. The amino tag of the INK101 DP peptide is also easily replaced by any peptide with BamHI and Ascl restriction sites, facilitating testing of any peptide-tag combination easily. The overall scheme to test fusion partner sequences was to design DNA oligonucleotides that when annealed generate the stick-ends required for directional cloning of the fusion partner in-frame with the test expression peptide.
An example of the methodology used to generate, test and score putative fusion partners follows. A nucleic acid molecule encoding an 11 amino acid sequence (SRRPRQLQQRQ; SEQ ID NO: 70) from a glutamine rich, amyloid-like protein from C. elegans was initially tested as a dimer (Inclusion Body Tag 3 (IBT-3);
SRRPRQLQQRQSRRPRQLQQRQ; SEQ ID NO: 67). IBT-3: was assembled from two complementary synthetic E. coli codon biased oligonucleotides (Sigma-Genosys).
IBT3+oligo: 5′-TATGAGCCGTCGTCCGCGTCAGTTGCAGCAGCGTCAGAGCCGTCGT CCGCGTCAGTTGCAGCAGCGTCAGG-3′ (SEQ ID NO: 19)
IBT3-oligo: 5′-GATCCCTGACGCTGCTGCAACTGACGCGGACGACGGCTCTGACGCT GCTGCAACTGACGCGGACGACGGCTCA-3′ (SEQ ID NO: 20)
Overhangs were included in each oligonucleotide as to generate cohesive end compatible with the restriction sites NdeI and BamHI.
The IBT3+ and IBT3− oligonucleotides were annealed by combining 100 pmol of each oligonucleotide in deionized water into one tube and heated in a water bath set at 99° C. for 10 minutes after which the water bath was turned off. The oligonucleotides were allowed to anneal slowly until the water bath reached room temperature (20-25° C.). The annealed oligonucleotides were diluted in 100 μL water prior to ligation into the test vector. The pLX121 vector was digested in Buffer 2 (New England Biolabs, Beverly Mass.) comprising 10 mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, 1 mM dithiothreitol (DTT); pH  ̃7.9) with the NdeI and BamHI restriction enzymes to release a 90 bp fragment corresponding to the original His6 containing inclusion body fusion partner and the linker from the parental pDEST17 plasmid that includes the att site of the GatewayTM Cloning System. The NdeI-BamHI fragments from the digested plasmid were separated by agarose gel electrophoresis and the vector was purified from the gel by using Qiagen QIAquick® Gel Extraction Kit (QIAGEN Valencia, Calif.; cat# 28704).
The diluted and annealed oligonucleotide (approximately 0.2 pmol) was ligated with T4 DNA Ligase (New England Biolabs Beverly, Mass.; catalog #M0202) to NdeI-BamHI digested, gel purified, plasmid pLX121 (approximately 50 ng) at 12° C. for 18 hours. DNA sequence analysis confirmed the expected plasmid sequence. The resulting plasmid (plasmid pLX147) comprised a chimeric gene (SEQ ID NO: 101) encoding the fusion peptide IBT 3-TBP101 (SEQ ID NO: 102).
The expression plasmid pLX147 was transformed into the arabinose inducible expression strain E. coli BL21-AI (Invitrogen; cat# C6070-03).
The expression vector was transferred into BL21-Al chemically competent E. coli cells for expression analysis. To produce the recombinant protein, 3 mL of LB-ampicillin broth (10 g/L bacto-tryptone, 5 g/L bacto-yeast extract, 10 g/L NaCl, 100 mg/L ampicillin; pH 7.0) was inoculated with one colony of the transformed bacteria and the culture was shaken at 37° C. until the OD600 reached 0.6. Expression was induced by adding 0.03 mL of 20% L-arabinose (final concentration 0.2%, Sigma-Aldrich, St. Louis, Mo.) to the culture and shaking was continued for another 3 hours. For whole cell analysis, 0.1 OD600 mL of cells were collected, pelleted, and 0.06 mL SDS PAGE sample buffer (1×LDS Sample Buffer (Invitrogen cat# NP0007), 6 M urea, 100 mM DTT) was added directly to the whole cells. The samples were heated at 99° C. for 10 minutes to solubilize the proteins. The solubilized proteins were then loaded onto 4-12% gradient MES NuPAGE® gels (NuPAGE® gels cat #NPO322, MES Buffer cat# NP0002; Invitrogen) and visualized with a Coomassie® G-250 stain (SimplyBlueTM SafeStain; Invitrogen; cat# LC6060).
Example 3
Verification of IBT-3 Induced Inclusion Body Formation
To verify that the fusion partner (IBT-3) drove expression into insoluble inclusion bodies, it was necessary to lyse the collected cells (0.1 OD600 mL of cells) and fractionate the insoluble from the soluble fraction by centrifugation. Cells were lysed using CelLyticTM Express (Sigma, St. Louis, Mo. cat# C-1990) according to the manufacturer's instructions. Cells that do not produce inclusion bodies undergo complete lysis and yielded a clear solution. Cells expressing inclusion bodies appeared turbid even after complete lysis.
The method used to rank the inclusion body tag was a subjective visual inspection of SimplyBlueTM SafeStain stained PAGE gels. The scoring system was 0, 1, 2 or 3. If no band is detected then a zero score is given. A score of three is given to very heavily stained wide expressed bands. Bands that are weak are scored a one and moderate bands are scored a two. Any score above zero indicated the presence of inclusion bodies.
Soluble and insoluble fractions were separated by centrifugation and analyzed by polyacrylamide gel electrophoresis and visualized with SimplyBlueTM SafeStain. Analysis of the cell protein by polyacrylamide gel electrophoresis shows the production of the IBT-3 fusion with TBP101 peptide was expressed insolubly since the appropriate MW band (17 kDa) was present in the whole cell and insoluble fraction but not in the soluble cell fraction (Expression ranking for IBT-3=2). This result suggested that it was possible to have very small fusion partners (10-30 amino acids) to facilitate production of peptides in inclusion bodies.
Example 4
Synthesis and Evaluation of Addition Inclusion Body Tags
A series of additional fusion proteins were prepared by fusing each of the following inclusion body tags (IBTs) to soluble peptide of interest using the methods described in Example 2. The sequence identification numbers of the oligos used to prepare the various IBTs are provided in Table 2. Expression ranking evaluation was conducted as described in Example 3. The results of the expression ranking experiments are provided in Table 4







TABLE 2







Oligonucleotide Sequences Used to Prepare the Various


Inclusion Body Tags













IBT Amino Acid


Inclusion Body

Oligonucleotide
Sequence


Tag
DNA strand
(SEQ ID NO)
(SEQ ID NO)





IBT-3
+
19
67


IBT-3
−
20


IBT-4
+
21
68


IBT-4
−
22


IBT-23
+
23
69


IBT-23
−
24


IBT-24
+
25
70


IBT-24
−
26


IBT-25
+
27
71


IBT-25
−
28


IBT-26
+
29
72


IBT-26
−
30


IBT-27
+
31
73


IBT-27
−
32


IBT-28
+
33
74


IBT-28
−
34


IBT-29
+
35
75


IBT-29
−
36


IBT-30
+
37
76


IBT-30
−
38


IBT-31
+
39
77


IBT-31
−
40


IBT-32
+
41
78


IBT-32
−
42


IBT-33
+
43
79


IBT-33
−
44


IBT-34
+
45
80


IBT-34
−
46


IBT-35
+
47
81


IBT-35
−
48


IBT-36
+
49
82


IBT-36
−
50


IBT-37
+
51
83


IBT-37
−
52


IBT-38
+
53
84


IBT-38
−
54


IBT-39
+
55
85


IBT-39
−
56


IBT-40
+
57
86


IBT-40
−
58


IBT-54
+
59
87


IBT-54
−
60


IBT-89
+
61
88


IBT-89
−
62


IBT-90
+
63
89


IBT-90
−
64


IBT-95
+
65
90


IBT-95
−
66









The nucleotide and amino acid sequences associated with each of the fusion proteins is provided in Table 3. An alignment of the present inclusion body tags is provided in Table 5.







TABLE 3







Fusion Protein Sequences












Fusion





Protein
Fusion Protein



Expression
Nucleic acid
Amino Acid



Plasmid
Sequence
Sequence


Fusion Protein
Designation
(SEQ ID NO.)
(SEQ ID NO.)













IBT 24-TBP101
pLX170
91
92


IBT 54-TBP101
pLX213
93
94


IBT 25-TBP101
pLX171
95
96


IBT 29-TBP101
pLX327
97
98


IBT 95-TBP101
pLX294
99
100


IBT 3-TBP101
pLX147
101
102


IBT 4-TBP101
pLX148
103
104


IBT 23-TBP101
pLX183
105
106


IBT 27-TBP101
pLX175
107
108


IBT 28-TBP101
pLX199
109
110


IBT 37-TBP101
pLX243
101
112


IBT 26-TBP101
pLX326
113
114


IBT 30-TBP101
pLX172
115
116


IBT 31-TBP101
pLX193
117
118


IBT 35-TBP101
pLX314
119
120


IBT 36-TBP101
pLX315
121
122


IBT 38-TBP101
pLX316
123
124


IBT 89-TBP101
pLX288
125
126


IBT 90-TBP101
pLX289
127
128


IBT 32-TBP101
pLX173
129
130


IBT 33-TBP101
pLX174
131
132


IBT 34-TBP101
pLX313
133
134


IBT 40-TBP101
pLX195
135
136
















TABLE 4







Inclusion Body Tag Expression Ranking









IBT Designation
Inclusion Body Tag Amino Acid Sequence (SEQ ID NO.)
Epression Ranking





IBT 24
SRRPRQLQQRQ
3



(SEQ ID NO:70)


 


IBT 54
SRRDPRQLQQRQ
3



(SEQ ID NO:87)


 


IBT 25
SRRPRQLQQRQDPSRRPRQLQQRQDPSRRPRQLQQRQ
3



(SEQ ID NO:71)


 


IBT 29
SEEPEQLQQEQSRRPRQLQQRQ
3



(SEQ ID NO:75)


 


IBT 95
SRRPRQLQQRQSLGYGGLYGY
3



(SEQ ID NO:90)


 


IBT 3
SRRPRQLQQRQSRRPRQLQQRQ
2



(SEQ ID NO:67)


 


IBT 4
SRRPRQLQQRQHHQQQQE
2



(SEQ ID NO:68)


 


IBT 23
SRRPRQLQQRQSRRPRQLQQRQSRRPRQLQQRQ
2



(SEQ ID NO:69)


 


IBT 27
SREPEQLQQRQSRRPEQLQQRQ
2



(SEQ ID NO:73)


 


IBT 28
SREPEQLQQRQSREPEQLQQRQ
2



(SEQ ID NO:74)


 


IBT 37
SRRPRQLQQRQSRRPRQLQQRQEEEE
2



(SEQ ID NO:83)


 


IBT 26
SRRPEQLQQRQSRRPEQLQQRQ
1



(SEQ ID NO:72)


 


IBT 30
SREPEQLQQEQSREPEQLQQRQ
1



(SEQ ID NO:76)


 


IBT 31
SREPEQLQQEQSREPEQLQQEQ
1



(SEQ ID NO:77)


 


IBT 35
SRRPRQLQQRQSRRPRQLQQRQEE
1



(SEQ ID NO:81)


 


IBT 36
SRRPRQLQQRQSRRPRQLQQRQEEE
1



(SEQ ID NO:82)


 


IBT 38
SRRPRQLQQRQSRRPRQLQQRQEEEEEE
1



(SEQ ID NO:84)


 


IBT 89
SRRPRQDPLQQRQDPSRRPRQLQQRQ
1



(SEQ ID NO:88)


 


IBT 90
SRRPRQDPLQQRQDPSRRPRQDPLQQRQ
1



(SEQ ID NO:89)


 


IBT 32
SREPEQLQQEQSEEPEQLQQEQ
0



(SEQ ID NO:78)


 


IBT 33
SEEPEQLQQEQSEEPEQLQQEQ
0



(SEQ ID NO:79)


 


IBT 34
SRRPRQLQQRQSRRPRQLQQRQE
0



(SEQ ID NO:80)


 


IBT 40
SRRPRQLQQRQSRRPRQLQQRQEEEEEEEEEE
0



(SEQ ID NO:86)
















TABLE 5





Inclusion Body Tag Sequence Alignment















IBT 24     --SRRPRQLQQRQ--------------------------


 


IBT 3      --SRRPRQLQQRQ--SRRPRQLQQRQ-------------


 


IBT 34     --SRRPRQLQQRQ--SRRPRQLQQRQE------------


 


IBT 35     --SRRPRQLQQRQ--SRRPRQLQQRQEE-----------


 


IBT 36     --SRRPRQLQQRQ--SRRPRQLQQRQEEE----------


 


IBT 37     --SRRPRQLQQRQ--SRRPRQLQQRQEEEE---------


 


IBT 38     --SRRPRQLQQRQ--SRRPRQLQQRQEEEEEE-------


 


IBT 40     --SRRPRQLQQRQ--SRRPRQLQQRQEEEEEEEEEE---


 


IBT 25     --SRRPRQLQQRQDPSRRPRQLQQRQDPSRRPRQLQQRQ


 


IBT 26     --SRRPEQLQQRQ--SRRPEQLQQRQ-------------


 


IBT 27     --SREPEQLQQRQ--SRRPEQLQQRQ-------------


 


IBT 28     --SREPEQLQQRQ--SREPEQLQQRQ-------------


 


IBT 29     --SEEPEQLQQEQ--SRRPRQLQQRQ-------------


 


IBT 30     --SREPEQLQQEQ--SREPEQLQQRQ-------------


 


IBT 31     --SREPEQLQQEQ--SREPEQLQQEQ-------------


 


IBT 32     --SREPEQLQQEQ--SEEPEQLQQEQ-------------


 


IBT 33     --SEEPEQLQQEQ--SEEPEQLQQEQ-------------


 


IBT 54     --------------SRRDPRQLQQRQ-------------


 


IBT 23     --SRRPRQLQQRQ--SRRPRQLQQRQSRRPRQLQQRQ--


 


IBT 89     SRRPRQDPLQQRQDPSRRPRQLQQRQ-------------


 


IBT 90     SRRPRQDPLQQRQDPSRRPRQDPLQQRQ-----------


 


IBT 4      ---------------SRRPRQLQQRQHHQQQQE------


 


IBT 95     ---------------SRRPRQLQQRQSLGYGGLYGY---

## Claims

1. An inclusion body tag comprising the structure:


[Ser-(Xaa1)-(Xaa2)-(Xaa3)-(Xaa4)-(Xaa5)-Leu-Gln-Gln-(Xaa6)-Gln]n 


wherein n=1-20,
and wherein
(Xaa1)=Arg or Glu;
(Xaa2)=Arg or Glu;
(Xaa3)=Pro or Gln;
(Xaa4)=Arg, Glu, or Asp
(Xaa5)=Gln or Pro;
(Xaa6)=Arg or Glu;
wherein the inclusion body tag does not have the amino acid sequence as set forth in SEQ ID NO:139.

2. The inclusion body tag of claim 1 having the amino acid sequence selected from the group consisting of SEQ ID NOS: 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 81, 82, 83, 84, 85, 88, 90, and 137.

3. A fusion peptide comprising the inclusion body tag of claim 1 operably linked to at least one peptide of interest.

4. The fusion peptide of claim 3, further comprising at least one cleavable peptide linker having at least one cleavage site.

5. The fusion peptide according to claim 3 wherein the peptide of interest is a hair binding peptide selected from the group consisting of SEQ ID NOS: 148 to 240.

6. The fusion peptide according to claim 3 wherein the peptide of interest is a skin binding peptide selected from the group consisting of SEQ ID NOS: 140 to 147.

7. The fusion peptide according to claim 3 wherein the peptide of interest is a nail binding peptide selected from the group consisting of SEQ ID NOS: 241 to 242.

8. The fusion peptide according to claim 3 wherein the peptide of interest is a polymer binding peptide selected from the group consisting of SEQ ID NOS: 298 to 331.

9. The fusion peptide according to claim 3 wherein the peptide of interest is an antimicrobial peptide selected from the group consisting of SEQ ID NOS: 243 to 271.

10. The fusion peptide according to claim 3 wherein the peptide of interest is a pigment binding peptide selected from the group consisting of SEQ ID NOS: 272-297.